Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914115087> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2914115087 abstract "273 Background: Substantial progress has been made in the understanding of the genomic landscape of PDAC, but the clinical utility of these data remains uncertain. Methods: As part of the BC Cancer Personalized Oncogenomics (POG) and PanGen studies, whole genome analysis and transcriptome sequencing were performed on fresh biopsy and blood sample from 47 mPDAC patients. Genomic findings informed therapy choices including potential eligibility for the CCTG PM.1 molecular basket trial. Results: Cohort consists of 53% male, average age 57.8, 34/47 had ≥2 lines of treatment. 37/47 biopsies were from liver and 26/47 were collected pre-treatment. 8/47 (17%) patients had aberrations with strong evidence of clinical actionability. These include 2 germline BRCA2, 1 germline BRCA1, 1 somatic XRCC2 homozygous deletion with strong COSMIC signature 3, all predictive of platinum sensitivity. Patients with XRCC2 deletion and BRCA1 had over 2 years on FOLFIRINOX. Fusions affecting the NRG1 gene were identified in 3 patients, all with KRAS wildtype tumours, which may confer ERRB inhibitor sensitivity. 1/3 NRG1 fusion patients had thus far been treated with the ERBB inhibitor afatinib, with reduction of CA19-9 from >120,000 to 7246 and dramatic response noted on PET CT imaging one month post treatment. One patient had mismatch repair deficiency, and a high mutational burden, suggestive of immune checkpoint inhibitor sensitivity. In total 85% (40/47) sequenced mPDAC patients had potentially actionable mutations which includes CCTG PM.1 trial eligibility: 24/47 with cell cycle dysregulation (CDK4/6 inhibitor arm), 4/47 with high homologous recombination defects (PARP inhibitor arm), 1/47 ERBB2 amplification (anti-HER2 arm), 2/47 high expression of FGFR1 (Sunitinib arm) and 1/47 with high FLT4 and IGF1R expression (Axitinib arm). Conclusions: More routine use of comprehensive genomic analysis should be considered in mPDAC given finding of high degree of actionability. Importantly, a significant proportion (17%) had findings with strong evidence of clinical impact.(NCT02155621, NCT02869802, NCT03297606)" @default.
- W2914115087 created "2019-02-21" @default.
- W2914115087 creator A5001731680 @default.
- W2914115087 creator A5015015784 @default.
- W2914115087 creator A5032239572 @default.
- W2914115087 creator A5036473360 @default.
- W2914115087 creator A5043250503 @default.
- W2914115087 creator A5044366354 @default.
- W2914115087 creator A5054009874 @default.
- W2914115087 creator A5062939544 @default.
- W2914115087 creator A5068084223 @default.
- W2914115087 creator A5068644454 @default.
- W2914115087 creator A5069667659 @default.
- W2914115087 creator A5070061359 @default.
- W2914115087 creator A5070331492 @default.
- W2914115087 creator A5081831776 @default.
- W2914115087 creator A5084671659 @default.
- W2914115087 creator A5085439016 @default.
- W2914115087 creator A5088331751 @default.
- W2914115087 creator A5089913686 @default.
- W2914115087 creator A5091086534 @default.
- W2914115087 creator A5091747658 @default.
- W2914115087 date "2019-02-01" @default.
- W2914115087 modified "2023-10-12" @default.
- W2914115087 title "Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations." @default.
- W2914115087 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.273" @default.
- W2914115087 hasPublicationYear "2019" @default.
- W2914115087 type Work @default.
- W2914115087 sameAs 2914115087 @default.
- W2914115087 citedByCount "0" @default.
- W2914115087 crossrefType "journal-article" @default.
- W2914115087 hasAuthorship W2914115087A5001731680 @default.
- W2914115087 hasAuthorship W2914115087A5015015784 @default.
- W2914115087 hasAuthorship W2914115087A5032239572 @default.
- W2914115087 hasAuthorship W2914115087A5036473360 @default.
- W2914115087 hasAuthorship W2914115087A5043250503 @default.
- W2914115087 hasAuthorship W2914115087A5044366354 @default.
- W2914115087 hasAuthorship W2914115087A5054009874 @default.
- W2914115087 hasAuthorship W2914115087A5062939544 @default.
- W2914115087 hasAuthorship W2914115087A5068084223 @default.
- W2914115087 hasAuthorship W2914115087A5068644454 @default.
- W2914115087 hasAuthorship W2914115087A5069667659 @default.
- W2914115087 hasAuthorship W2914115087A5070061359 @default.
- W2914115087 hasAuthorship W2914115087A5070331492 @default.
- W2914115087 hasAuthorship W2914115087A5081831776 @default.
- W2914115087 hasAuthorship W2914115087A5084671659 @default.
- W2914115087 hasAuthorship W2914115087A5085439016 @default.
- W2914115087 hasAuthorship W2914115087A5088331751 @default.
- W2914115087 hasAuthorship W2914115087A5089913686 @default.
- W2914115087 hasAuthorship W2914115087A5091086534 @default.
- W2914115087 hasAuthorship W2914115087A5091747658 @default.
- W2914115087 hasConcept C121608353 @default.
- W2914115087 hasConcept C126322002 @default.
- W2914115087 hasConcept C143998085 @default.
- W2914115087 hasConcept C190283241 @default.
- W2914115087 hasConcept C2777148230 @default.
- W2914115087 hasConcept C2777609662 @default.
- W2914115087 hasConcept C2780210213 @default.
- W2914115087 hasConcept C2780259306 @default.
- W2914115087 hasConcept C2781182431 @default.
- W2914115087 hasConcept C2781187634 @default.
- W2914115087 hasConcept C502942594 @default.
- W2914115087 hasConcept C526805850 @default.
- W2914115087 hasConcept C54355233 @default.
- W2914115087 hasConcept C71924100 @default.
- W2914115087 hasConcept C86554907 @default.
- W2914115087 hasConcept C86803240 @default.
- W2914115087 hasConceptScore W2914115087C121608353 @default.
- W2914115087 hasConceptScore W2914115087C126322002 @default.
- W2914115087 hasConceptScore W2914115087C143998085 @default.
- W2914115087 hasConceptScore W2914115087C190283241 @default.
- W2914115087 hasConceptScore W2914115087C2777148230 @default.
- W2914115087 hasConceptScore W2914115087C2777609662 @default.
- W2914115087 hasConceptScore W2914115087C2780210213 @default.
- W2914115087 hasConceptScore W2914115087C2780259306 @default.
- W2914115087 hasConceptScore W2914115087C2781182431 @default.
- W2914115087 hasConceptScore W2914115087C2781187634 @default.
- W2914115087 hasConceptScore W2914115087C502942594 @default.
- W2914115087 hasConceptScore W2914115087C526805850 @default.
- W2914115087 hasConceptScore W2914115087C54355233 @default.
- W2914115087 hasConceptScore W2914115087C71924100 @default.
- W2914115087 hasConceptScore W2914115087C86554907 @default.
- W2914115087 hasConceptScore W2914115087C86803240 @default.
- W2914115087 hasLocation W29141150871 @default.
- W2914115087 hasOpenAccess W2914115087 @default.
- W2914115087 hasPrimaryLocation W29141150871 @default.
- W2914115087 hasRelatedWork W1819065859 @default.
- W2914115087 hasRelatedWork W1993312852 @default.
- W2914115087 hasRelatedWork W2092855648 @default.
- W2914115087 hasRelatedWork W2145917927 @default.
- W2914115087 hasRelatedWork W2170040778 @default.
- W2914115087 hasRelatedWork W2326355605 @default.
- W2914115087 hasRelatedWork W2339974010 @default.
- W2914115087 hasRelatedWork W2586119928 @default.
- W2914115087 hasRelatedWork W2976478313 @default.
- W2914115087 hasRelatedWork W2992551862 @default.
- W2914115087 isParatext "false" @default.
- W2914115087 isRetracted "false" @default.
- W2914115087 magId "2914115087" @default.
- W2914115087 workType "article" @default.